Ondine Biomedical Inc (OBI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ondine Biomedical Inc (OBI) has a cash flow conversion efficiency ratio of -0.665x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-4.57 Million ≈ $-556.42 USD) by net assets (GBX6.88 Million ≈ $836.73 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ondine Biomedical Inc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Ondine Biomedical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Ondine Biomedical Inc (OBI) financial obligations for a breakdown of total debt and financial obligations.
Ondine Biomedical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ondine Biomedical Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Colefax Group
LSE:CFX
|
0.297x |
|
Vivanco Gruppe AG
F:VG0K
|
0.164x |
|
GlucoTrack Inc
NASDAQ:GCTK
|
-1.680x |
|
Brain+ ApS
CO:BRAINP
|
-0.964x |
|
ALGERNON PHARMACEUT. A
F:AGW0
|
N/A |
|
Bitcoin Fund Unit
TO:QBTC
|
-0.019x |
|
Maven Income And Growth Vct 5 Plc
LSE:MIG5
|
-0.005x |
|
Windtree Therapeutics Inc
NASDAQ:WINT
|
0.549x |
Annual Cash Flow Conversion Efficiency for Ondine Biomedical Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of Ondine Biomedical Inc from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see OBI company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX6.88 Million ≈ $836.73 |
GBX-15.49 Million ≈ $-1.88K |
-2.252x | +65.60% |
| 2023-12-31 | GBX2.08 Million ≈ $253.68 |
GBX-13.65 Million ≈ $-1.66K |
-6.548x | -366.49% |
| 2022-12-31 | GBX11.64 Million ≈ $1.42K |
GBX-16.34 Million ≈ $-1.99K |
-1.404x | -231.98% |
| 2021-12-31 | GBX29.66 Million ≈ $3.61K |
GBX-12.54 Million ≈ $-1.53K |
-0.423x | -325.93% |
| 2020-12-31 | GBX-33.83 Million ≈ $-4.12K |
GBX-6.33 Million ≈ $-770.30 |
0.187x | -35.38% |
| 2019-12-31 | GBX-26.07 Million ≈ $-3.17K |
GBX-7.55 Million ≈ $-918.74 |
0.290x | -48.60% |
| 2018-12-31 | GBX-17.90 Million ≈ $-2.18K |
GBX-10.08 Million ≈ $-1.23K |
0.563x | -29.97% |
| 2017-12-31 | GBX-6.55 Million ≈ $-796.70 |
GBX-5.27 Million ≈ $-640.96 |
0.805x | +108.26% |
| 2010-12-31 | GBX279.19K ≈ $33.97 |
GBX-2.72 Million ≈ $-330.96 |
-9.743x | -262.05% |
| 2009-12-31 | GBX1.28 Million ≈ $155.48 |
GBX-3.44 Million ≈ $-418.39 |
-2.691x | +59.70% |
| 2008-12-31 | GBX1.34 Million ≈ $162.71 |
GBX-8.93 Million ≈ $-1.09K |
-6.677x | -508.20% |
| 2007-12-31 | GBX10.84 Million ≈ $1.32K |
GBX-11.90 Million ≈ $-1.45K |
-1.098x | -67.96% |
| 2006-12-31 | GBX16.59 Million ≈ $2.02K |
GBX-10.84 Million ≈ $-1.32K |
-0.654x | -28.61% |
| 2005-12-31 | GBX16.50 Million ≈ $2.01K |
GBX-8.39 Million ≈ $-1.02K |
-0.508x | -274.72% |
| 2003-08-31 | GBX-227.62K ≈ $-27.70 |
GBX-66.20K ≈ $-8.06 |
0.291x | +264.97% |
| 2002-08-31 | GBX-143.28K ≈ $-17.43 |
GBX25.26K ≈ $3.07 |
-0.176x | -396.57% |
| 2001-08-31 | GBX1.39 Million ≈ $169.63 |
GBX-49.50K ≈ $-6.02 |
-0.036x | -- |
About Ondine Biomedical Inc
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more